A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06234423

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06234423. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Study identification

NCT ID: NCT06234423
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: OnCusp Therapeutics, Inc.; Industry
Enrollment: 263 participants

Conditions and interventions

Conditions

Interventions

CUSP06 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 9, 2024 (Actual)
Primary completion: May 30, 2027 (Estimated)
Completion: Oct 31, 2027 (Estimated)
Last update posted: Jan 14, 2026

2024 – 2027

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Sarah Cannon Research Institute at HealthONE	Denver	Colorado	80218	Recruiting
Yale University	New Haven	Connecticut	06520	Recruiting
Mount Sinai Medical Center	Miami Beach	Florida	33140	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02115	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
NYU Cancer Institute Clinical Cancer Center	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021	Recruiting
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology	Houston	Texas	77054	Recruiting
START San Antonio	San Antonio	Texas	78229	Recruiting
NEXT Oncology	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06234423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2026 · Synced Nov 14, 2026